Title: Analysis of phage therapy failure in a patient with a Pseudomonas 1 2 aeruginosa prosthetic vascular graft infection 3 Authors: Lucia Blasco¹, Inmaculada López-Hernández^{2,3}, Miguel Rodríguez-4 Fernández⁴, Javier Pérez-Florido^{5,6}, Carlos S. Casimiro-Soriguer^{5,6}, Sarah 5 Djebara⁷, Maya Merabishvili⁷, Jean-Paul Pirnay⁷, Jesús Rodríguez-Baño^{2,3}, 6 María Tomás^{1&*}, Luis Eduardo López Cortés^{2,3&} 7 8 9 1. Translational and Multidisciplinary Microbiology (MicroTM)-Biomedical Research Institute (INIBIC); Microbiology Service, A Coruña Hospital (HUAC); 10 University of A Coruña (UDC), A Coruña, Spain. 11 12 2. Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena; Departamentos de Medicina y Microbiología, 13 Facultad de Medicina, Universidad de Sevilla; and Instituto de Biomedicina de 14 Sevilla (IBiS)/CSIC, Seville, Spain. 15 CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain 16 3. 17 4. Unit of Infectious Diseases and Microbiology, Valme University Hospital, Institute of Biomedicine of Sevilla, Seville, Spain. 18 19 5. Computational Medicine Platform, Andalusian Public Foundation Progress and 20 Health-FPS, 41013 Sevilla, Spain 21 22 6. Computational Systems Medicine, Institute of Biomedicine of Seville, IBiS, University Hospital Virgen del Rocío/CSIC/University of Sevilla, 41013 Sevilla, 23 24 Spain 25 26 7. Laboratory for Molecular and Cellular Technology, Queen Astrid Military 27 Hospital, Neder-over-Heembeek, Belgium 28 29 ^aThese researchers contributed equally to the work as senior authors *Correspondence: Maria Tomás 30 Email: MA.del.Mar.Tomas.Carmona@sergas.es; 31 Tel.: +34 981176399; Fax: +34 981178273. 32 33 **Keywords:** Phage; phage therapy; antibiotic resistance; *Pseudomonas* 34 aeruginosa; bypass; prosthetic vascular graft infection 35 36

37 Abstract

38 Clinical case of a patient with a *Pseudomonas aeruginosa* multidrug-resistant 39 prosthetic vascular graft infection which was treated with a cocktail of phages (PT07, 14/01 and PNM) in combination with ceftazidime-avibactam (CAZ/AVI). 40 After the application of the phage treatment and in absence of antimicrobial 41 therapy, a new *P. aeruginosa* bloodstream infection (BSI) with a septic residual 42 43 limb metastasis occurred, now involving a wild-type strain being susceptible to ß-lactams and guinolones. Clinical strains were analyzed by microbiology and 44 whole genome sequencing techniques. In relation with phage administration, 45 the clinical isolates of *P. aeruginosa* before phage therapy (HE2011471) and 46 post phage therapy (HE2105886) showed a clonal relationship but with 47 48 important genomic changes which could be involved in the resistance to this 49 therapy. Finally, phenotypic studies showed a decreased in Minimum Inhibitory 50 Concentration (MIC) to ß-lactams and quinolones as well as an increase of the 51 biofilm production and phage resistant mutants in the clinical isolate of P. 52 aeruginosa post phage therapy.

53 **Importance**

54 Phage therapy is a promising new treatment against infections produced by multi-drug resistant pathogens. For that, it would be necessary to know more 55 about the clinical response and host-phage interactions by massive sequencing 56 techniques to improve phage therapy application. In this work, we analyzed the 57 58 clinical, microbiological and molecular features of the *P. aeruginosa* isolates in 59 prosthetic vascular graft infection after the phages administration failure against 60 this infection. This knowledge could allow to develop strategies of improvement 61 of the use of phage therapy as treatment of multiple clinical infections.

- 62
- 63
- 64
- 65
- 66

67 We present the case of a in their 50s man who in July 2020 developed a 68 surgical infection caused by ceftazidime and piperacillin-tazobactam resistant Pseudomonas aeruginosa. In August 2020, an axillo-bifemoral bypass was 69 70 performed. Shortly afterwards, the patient developed a bloodstream infection (BSI) caused by *P. aeruginosa* with the same antibiotic resistance pattern, 71 72 originating from a sacral ulcer, which was treated with meropenem (1g, g8h for 73 17 days). The patient suffered up to five recurrences of *P. aeruginosa* BSI 74 between October and December 2020, while the sacral ulcer developed 75 favourably. After the second relapse, 18F-fluorodeoxyglucose (18F-FDG) PET/CT was performed, showing pathological radioactive-labelled glucose 76 77 uptake along the preclavicular graft region (SUVmax value, 5.29) and 78 suggesting prosthetic vascular graft infection (PVGI). Nevertheless, surgical 79 management was rejected. The patient subsequently received different targeted antibiotherapies for two to six weeks (Figure 1). Two new P. aeruginosa BSI 80 relapses occurred between March and May 2021. Ceftolozane-tazobactam was 81 82 not used (not available), and off-label tebipenem use was denied; treatment was therefore as shown in Figure 1. Simultaneously, therapeutic phages were 83 84 obtained from the Queen Astrid Military Hospital (Brussels, Belgium) in view of a possible compassionate use phage therapy. Phage susceptibility of the 85 86 clinical isolate was determined in the A Coruña University Hospital, and three P. aeruginosa phages (PT07, 14/01 and PNM) were selected [1, 2]. In July 2021, 87 70 ml of the bacteriophage cocktail, consisting of the three phages, each at a 88 concentration of 10⁷ plaque forming units (PFU)/mL, was administered 89 90 intravenously, once a day in a 6-hour infusion for three days in an inpatient regimen. No adverse events were observed. Phage therapy was followed by 91 four days of outpatient parenteral antimicrobial therapy (OPAT) at the patient's 92 request. Ceftazidime-avibactam was applied for 8 weeks (6 weeks before and 2 93 94 weeks after the phage therapy). In August 2021, in the absence of antimicrobial 95 therapy, a new P. aeruginosa BSI with a septic residual limb metastasis occurred, now involving a wild-type strain being susceptible to ß-lactams and 96 quinolones. Finally, upon a multidisciplinary discussion, a proximal vascular 97 prosthesis replacement combined with antibiotherapy in OPAT was performed. 98 99 Currently, after ten months without treatment, the patient remains 100 asymptomatic.

101 Eight blood culture isolates obtained between November 2020 and August 2021 102 were characterized by microbiological analysis. These isolates were identified by matrix assisted laser desorption/ionisation - time of flight mass spectrometry 103 104 (MALDI-TOF MS, Bruker Daltonics) as P. aeruginosa. Antimicrobial susceptibility testing was performed by broth microdilution (Microscan, 105 Beckman Coulter) and interpreted using European Committee on Antimicrobial 106 107 Susceptibility Testing (EUCAST) criteria. Pulsed-field gel electrophoresis (PFGE) revealed that four representative isolates from 2020 and 2021, were 108 109 clonal (Figure S1). Genomic sequence of five representative isolates showed that these isolates belonged to the high-risk clone ST308 with core genome 110 MLST (MLST)cqST2675. A search for antimicrobial resistance genes in the 111 112 ResFinder database did not identify any acquired resistance genes such as ß-113 lactamases. Analysis of 40 chromosomal resistance genes revealed natural polymorphisms in numerous genes, including some changes with unknown 114 effect [3]. The profile of all isolates was identical for all genes studied, except for 115 the nfxB gene (a transcriptional repressor that regulates MexCD-OprJ), in which 116 multiple amino acid changes were observed in the last 3 isolates (Table S1, 117 Figure S2). Moreover, comparison of the genomes of isolates HE2011471 118 (previous to phage administration) and HE2105886 (one month after phage 119 120 treatment) revealed important mutations (Figure 2). Interestingly, several detected genomic changes could be involved in phage resistance (Table S2, 121 Figure 3). Isolate HE2105886, recovered one month after phage treatment, 122 123 exhibited a decrease in the Minimum Inhibitory Concentration (MICs) of ß-124 lactam and quinolone antibiotics (Figure 1), an increased biofilm formation (Figure S3A), and an increased frequency of occurrence of phage resistant 125 mutants (Figure S3B) [4]. 126

127 **DISCUSSION**

This case highlights three key issues. The first relates to the use of combined therapy versus monotherapy as a definitive treatment for *P. aeruginosa* BSI. So far, combination therapy has not been associated with reduced mortality or any advantages in terms of clinical outcome or successful treatment of recurrent/persistent bacteraemia [5]. The second issue concerns prosthetic vascular graft infection (PVGI) diagnosis and its best management. At the early

stages of PVGI, a high degree of suspicion is essential. Indium-111-labelled 134 135 white blood cell scintigraphy plus single-photon emission computed tomography (SPECT/CT) could reduce the false positive rates observed with PET/CT [6]. In 136 the present case, PET/CT was not performed at the early postoperative stage, 137 because of the possibility of a false positive result. Regarding the treatment, 138 graft excision is the preferred surgical approach. However, some patients are 139 140 considered unacceptable surgical candidates due to underlying comorbidities or technically unfeasible surgery. When this occurs, lifelong suppressive 141 142 antimicrobial therapy is an option, but is not free of side-effects or the risk of development of antimicrobial resistance. As the patient was initially denied 143 surgical treatment, long-term suppressive treatment with guinolones was 144 145 administered. However, ciprofloxacin-resistance developed, and surgery was 146 finally deemed key to a favourable outcome. Furthermore, there is no evidencebased recommendation for either PVGI antimicrobial treatment or its optimal 147 duration; minimum intravenous therapy for 6 weeks followed by oral 148 antibiotherapy for up to 6 months has been proposed [7, 8]. ¹⁸F-FDG PET/CT-149 guided treatment duration seems feasible and would allow treatment to be 150 tailored to individual patients [9]. The third highlighted issue is related to phage 151 therapy. Phage therapy involves the targeted application of strictly virulent 152 153 phages that can specifically infect and lyse the targeted pathogenic bacteria they encounter, hereby releasing virion progeny that continues the lytic cycle. A 154 155 major advantage of phages is the minimal impact on non-target bacteria or body 156 tissues [10]. A recent systematic review suggested that phage therapy is safe and may be effective in different difficult-to-treat infections [11]. Interestingly, a 157 previously-reported case of ß-lactam resistance in an MDR P. aeruginosa 158 isolate causing an aortic graft infection was reverted after treatment with a 159 phage that appeared to utilize the outer membrane protein M (OprM) of the 160 MexAB- and MexXY-multidrug efflux pumps, associated with antibiotic 161 resistance, a as receptor, and which was no longer expressed in the selected 162 phage-resistant bacterial strain [12]. In the present case, even though phage 163 therapy did not cure the infection, the posterior infection recurrence was caused 164 by an antibiotic susceptible isolate that belonged to the same lineage as the one 165 166 that was causing the pre-phage treatment episodes of infection. However, the 167 recurrent isolate was recovered one month after the phage therapy, and it is

168 possible that the resensitization (to ß-lactams and guinolones) could have been 169 due to a spontaneous evolution of the resident strain. Further studies are necessary to elucidate whether the genomic changes found in the bacteria are 170 171 responsible for the change in phenotype and are related to the phage therapy. One strength of this study is that phage therapy was able to be safely 172 administered in OPAT for greater patient convenience. To our knowledge, this 173 174 has only been reported once before, in a series of six cases, without phagerelated adverse events [13]. The main limitations our study were: first, we did 175 176 not perform in vitro studies of the effect of the phages in combination with antibiotics, specially ß-lactams; second, we could not study the P. aeruginosa 177 clinical isolates during the seven days of application of phage therapy. Finally, it 178 179 should be noticed that there are no national or local phage bank with 180 characterized phages against P. aeruginosa in which specific phages could be selected to provide personalized approach in patients with complex infections 181 caused by these bacteria. In conclusion, in complex P. aeruginosa infections 182 the choice of antibiotic therapy and its duration are crucial for minimizing 183 184 antibiotic pressure and development of resistance. Although we have not demonstrated that phage treatment was effective in this case, studying the 185 molecular mechanisms of resistance to phages and bacteria-phage interactions 186 187 are key to improving phage therapy in the near future.

188 MATERIAL/METHODS

189 Microbiology studies

The isolates were identified by MALDI-TOF MS (Bruker Daltonics). Antimicrobial susceptibility testing was performed by broth microdilution with a Microscan system (Beckman Coulter), and the results were interpreted according to the clinical breakpoints defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). PFGE analysis was performed using *Spel*.

Genomic sequencing and bioinformatic tools

Whole genome sequencing of the five isolates was performed in a HiSeq 2500
sequencing system (Illumina), and sequences were assembled using SPAdes
3.10.1.

Clonality testing of genomes was carried out using MLST Finder (from CGE, 200 available at https://bitbucket.org/genomicepidemiology/mlst/src/master/) and 201 Ridom SegSphere+ v8.5, and the resistance mechanisms were analyzed using 202 the ResFinder database. SNP calling was performed using snippy v4.6.0 203 against the NCBI PGAP 204 annotation (https://www.ncbi.nlm.nih.gov/genome/annotation prok/). The assemblies were 205 visually inspected using Bandage v0.8.1. (https://rrwick.github.io/Bandage/). 206 207 Further functional annotation genes and prophage elements were confirmed 208 using Blastx (http://blast.ncbi.nlm.nih.gov), Hhmer (http://hmmer.org) and also the HHpred tool (https://toolkit.tuebingen.mpg.de/tools/hhpred), which predict 209 functions through protein structure. 210

Assembled genomes of *P. aeruginosa* isolates were analyzed using Phaster (PHAge Search Tool Enhanced Release) software (<u>https://phaster.ca/</u>) and SourceFinder (https://cge.food.dtu.dk/services/SourceFinder/).

214 **Biofilm production**

Overnight cultures of *P. aeruginosa* isolates HE2011471 and HE2105886 were 215 216 diluted 1:100 and used to inoculate 100 µL of LB broth in a 96 multi-well plate. 217 The plate was incubated for 24 h at 37 °C in darkness. The supernatant was discarded and the wells were washed with PBS. One hundred µL of methanol 218 was then added to each well and discarded after 10 min. When the methanol 219 had completely evaporated, 100 µL of crystal violet (0.1%) was added and 220 221 discarded after 15 min. Finally, the wells were washed with PBS before the addition of 150 µL of acetic acid (30%), and the absorbance was measured at 222 223 OD 585 nm.

224 Frequency of occurrence of phage resistant mutants

The frequency of occurrence of phage resistant mutants was determined as previously described, with some modifications [14]. Overnight cultures of isolates HE2011471 and HE 2105886 were diluted 1:100 in LB and grown to an OD600nm of 0.6–0.7. An aliquot of 100 μ L of the culture containing 10⁸ colony forming units (CFU)/mL was serially diluted, and each dilution was mixed with 100 μ L of 10⁹ PFU/mL phage cocktail and then plated by the agar overlay method [15]. The plates were incubated at 37 °C for 18 h and the number of

CFUs was counted. The frequency of occurrence of phage resistant mutants
and phage resistant mutants was calculated by dividing the number of resistant
bacteria by the total number of sensitive bacteria.

235

236 ACKNOWLEDGEMENTS

We are grateful to Juan Manuel Carmona-Caballero (Hospital Universitario 237 238 Virgen del Rocío), Elena Fraile (Hospital Universitario Virgen del Rocío), 239 Vicente Merino-Bohorquez (Hospital Universitario Virgen Macarena) and Zaira 240 Palacios-Baena (Hospital Universitario Virgen Macarena) for clinical assistance. We also thank to Carlos Velázquez-Velázquez (Hospital Universitario Virgen 241 242 Macarena) and Jose Miguel Barguero-Aroca (Hospital Universitario Virgen 243 Macarena) for the surgical assistance. Phage studies were financed by grants 244 PI19/00878 and PI22/00323 awarded to M. Tomás within the State Plan for 245 R+D+I 2013-2016 (National Plan for Scientific Research, Technological 246 Development and Innovation 2008-2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research-European 247 Regional Development Fund "A way of Making Europe" and Instituto de Salud 248 249 Carlos III FEDER, Spanish Network for the Research in Infectious Diseases (CIBER CB21/13/00012 and CIBER project PMP22/00092), and by the Study 250 Group on Mechanisms of Action and Resistance to Antimicrobials, GEMARA 251 252 (SEIMC, <u>http://www.seimc.org/</u>). L.E.L.C. and J.R.B. were supported by Plan Nacional de I+D+I 2013-2016 and Instituto de Salud Carlos III, Subdirección 253 254 General de Redes y Centros de Investigación Cooperativa, Ministerio de 255 Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (RD16/0016/0001)-co-financed by European Development 256 Regional Fund 'A way to achieve Europe, Operative program Intelligent Growth 257 2014-2020'. 258

259 TRANSPARENCY DECLARATIONS

260 The authors declare that they have no conflicts of interest.

261 DATA AVAILABILITY

All data generated or analyzed during this study are included in this published article [and its supplementary information files]. Bacterial genomes of *Pseudomonas aeruginosa* isolates HE2105886 (after phage treatment) in

comparison with HE2011471 (previous to phages administration) are deposited

266 in the GenBank Bioproject PRJNA938043

267 (https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA938043).

268 ETHICAL APPROVAL

Medical Direction of Hospital Universitario Virgen Macarena approved the phage therapy in this patient and after signing the informed consent by the patient by use of experimental medication as compassionate use.

272 **FIGURES**

Figure 1. Timeline depicting the different antibiotic and phage therapies, the 273 274 isolation of *Pseudomonas aeruginosa* strains from blood cultures and their antibiotic susceptibility and genomic analyses. PFGE of these strains in 275 described in the Figure S1. ¹Completed in outpatient parenteral antibiotic 276 ³MIC: 277 treatment. ²CAZ/AVI: Ceftazidime-avibactam. Minimum inhibitory 278 concentration. ⁴P/T: Piperacillin-tazobactam. Whole Genome Sequences (WGS) is shown in Black Genome Sequences (three clinical isolates) and Red 279 Genome Sequences, which are bacterial genomes of Pseudomonas aeruginosa 280 isolates in relation with phage therapy (two clinical isolates): HE2105886 (after 281 282 phage treatment) in comparison with HE2011471 (prior to phage 283 administration).

Figure 2. Circular chromosomic view of the bacterial genomes of two *Pseudomonas aeruginosa* isolates: HE2105886 (after phage treatment) in comparison with HE2011471 (prior to phage administration).

Figure 3. Graphic representation of the proteins coded by the HE2105886 genome with an emphasis of changes associated with mechanisms of resistance and response to phage infection.

290 SUPPLEMENTARY MATERIAL

Figure S1. PFGE (*Pulsed Field Gel Electrophoresis*) patterns of four sequential
 Pseudomonas aeruginosa isolates.

Figure S2. Amino acid changes in NfxB.

Figure S3. Comparison of the biofilm production (A) and the frequency of occurrence of phage resistant mutants(B) between the *Pseudomonas aeruginosa* isolates HE2011471 (pre phage therapy) and HE2105886 (post phage therapy). **** p value < 0.001 (GraphPad Prism 9.0.0).

Table S1. Mutations encountered in proteins known to be related to antimicrobial resistance in *Pseudomonas aeruginosa.*

Table S2. Mutations encountered in proteins supposed to be related to phage resistance in response to lytic phage infection in *P. aeruginosa.* ^a Proteins located in prophages as identified by Phaster and SourceFinder.

- 304
- 305
- 306
- 307
- 308
- 309
- 310
- 311
- 312
- 313

314

315

- 316
- 317
- 318
- 319
- 320

321 **REFERENCES**

- 1. PJ Ceyssens, T Glonti, NM Kropinski, R Lavigne, N Chanishvili, L Kulakov, et
- al. Phenotypic and genotypic variations within a single bacteriophage species.
- 324 Virol J. 2011; 8:134. <u>https://doi.org/10.1186/1743-422X-8-134</u>.
- 325 2. PJ Ceyssens, K Miroshnikov, W Mattheus, V Krylov, J Robben, JP Noben, et
- al. Comparative analysis of the widespread and conserved PB1-like viruses
- infecting *Pseudomonas aeruginosa*. Environ Microbiol. 2009; 11(11): 2874-83.
- 328 <u>https://doi.org/10.1111/j.1462-2920.2009.02030.x</u> .
- 329 3. Cortes-Lara S, Barrio-Tofiño ED, López-Causapé C, Oliver A; GEMARA-

330 SEIMC/REIPI Pseudomonas study Group. Predicting Pseudomonas aeruginosa

- 331 susceptibility phenotypes from whole genome sequence resistome analysis.
- 332
 Clin
 Microbiol
 Infect.
 2021
 Nov;27(11):1631-1637.

 333
 https://doi.org/10.1016/j.cmi.2021.05.011

 </td
- **4.** M Castledine, D Padfield, P Sierocinski, J Soria Pascual, A Hughes, L Mäkinen, et al. Parallel evolution of *Pseudomonas aeruginosa* phage resistance
- and virulence loss in response to phage treatment in vivo and in vitro. Elife.
 2022; 11: e73679. <u>https://doi.org/10.7554/eLife.73679</u>
- 5. Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, et al.
 Combination versus monotherapy as definitive treatment for *Pseudomonas aeruginosa* bacteraemia: a multicentre retrospective observational cohort study.
 J Antimicrob Chemother. 2021; 76 (8): 2172-81.
- 342 <u>https://doi.org/10.1093/jac/dkab134</u>
- 6. Reinders Folmer EI, Von Meijenfeldt GCI, Van der Laan MJ, Glaudemans
 AWJM, Slart RHJA, Saleem BR, et al. Diagnostic Imaging in Vascular Graft
 Infection: A Systematic Review and Meta-Analysis. Eur J Vasc Endovasc Surg.
 2018; 56 (5): 719-29. <u>https://doi.org/10.1016/j.ejvs.2018.07.010</u>
- 7. Leroy O, Meybeck A, Sarraz-Bournet B, d'Elia P, Legout L. Vascular graft
 infections. Curr Opin Infect Dis. 2012; 25 (2): 154-8. <u>https://doi.org/</u>
 <u>10.1097/QCO.0b013e3283501853</u>

8. Wilson WR, Bower TC, Creager MA, Amin-Hanjani S, O'Gara PT, Lockhart
PB, et al. Vascular Graft Infections, Mycotic Aneurysms, and Endovascular
Infections: A Scientific Statement From the American Heart Association.
Circulation. 2016; 134 (20): e412-60. <u>https://doi.org/</u>
10.1161/CIR.00000000000457.

9. Kung BT, Seraj SM, Zadeh MZ, Rojulpote C, Kothekar E, Ayubcha C, et al.
An update on the role of ¹⁸F-FDG-PET/CT in major infectious and inflammatory
diseases. Am J Nucl Med Mol Imaging. 2019; 9 (6): 255-73. eCollection 2019.

10. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human
infections. Bacteriophage. 2011; 1 (2): 66-85. <u>https://doi.org/</u>
10.4161/bact.1.2.15845.

11. Uyttebroek S, Chen B, Onsea J, Ruythooren F, Debaveye Y, Devolder D, et
al. Safety and efficacy of phage therapy in difficult-to-treat infections: a
systematic review. Lancet Infect Dis. 2022; S1473-3099(21)00612-5.
<u>https://doi.org/10.1016/S1473-3099(21)00612-5.</u>

12. Chan BK, Turner PE, Kim S, Mojibian HR, Elefteriades JA, Narayan D.
Phage treatment of an aortic graft infected with *Pseudomonas aeruginosa*. Evol
Med Public Health. 2018; 2018 (1): 60-6. <u>https://doi.org/10.1093/emph/eoy005.</u>

Aslam S, Lampley E, Wooten D, Karris M, Benson C, Strathdee S, et al.
Lessons Learned from the First 10 Consecutive Cases of Intravenous
Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a
Single Center in the United States. Open Forum Infect Dis. 2020; 7 (9):
ofaa389. https://doi.org/10.1093/ofid/ofaa389.

14. Blasco L, Ambroa A, Lopez M, Fernandez-Garcia L, Bleriot I, Trastov R, 373 374 Ramos-Vivas J, Coenye T, Fernandez-Cuenca F, Vila J, Martinez-Martinez L, Rodriguez-Baño J, Pascual A, Cisneros JM, Pachon J, Bou G, Tomas M. 375 Combined Use of the Ab105-2 $\phi\Delta$ CI Lytic Mutant Phage and Different 376 Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii. 377 Microorganisms. 2019 Nov 378 12;7(11):556. https://doi.org/ 379 10.3390/microorganisms7110556.

- 380 15. Kropinski AM, Mazzocco A, Waddell TE, Lingohr E, Johnson RP.
- 381 Enumeration of bacteriophages by double agar overlay plaque assay. Methods
- 382 Mol Biol. 2009; 501:69-76. <u>https://doi.org/10.1007/978-1-60327-164-6_7.</u>

383

384



385

Figure 1.

387



389 Figure 2.



390

391 Figure 3.



CLUSTAL O(1.2.4) multiple sequence alignment

PAO1nfxB	DTLISHDERLIKALAVAIVDRPRATLKELAEAAGVSKA	38
HE2011311	MTLAPRSAQLPDSPHKDSLDPAPTPSSQDQRLLKALATAMVNHPRATMGELAELAGVSRA	60
HE2011471	MTLAPRSAQLPDSPHKDSLDPAPTPSSQDQRLLKALATAMVNHPRATMGELAELAGVSRA	60
HE2105886	MTLAPRSAQLPDSPHKDSLDPAPTPSSQDQRLLKALATAMVNHPRATMGELAELAGVSRA	60
	* * * * * * * * * * * * * * * * * * * *	
PAO1nfxB	TLHRFCGTRDNLVQMLEDHGETVLNQIIQACDLEHAEPLEALQRLIKEHLTHRELLVFLV	98
HE2011311	TLNRHCGTREGLKRRLESHARSTLERLTHSAALQRLEPREALRELIREHLAQRDLLALLM	120
HE2011471	TLNRHCGTREGLKRRLESHARSTLERLTHSAALQRLEPREALRELIREHLAQRDLLALLM	120
HE2105886	TLNRHCGTREGLKRRLESHARSTLERLTHSAALQRLEPREALRELIREHLAQRDLLALLM	120
	:*.*:.* : **.**::: ::. *:: ** ***:.**:**:*:*:*:	
PAO1nfxB	FQYRPDFLDPHGEGARWQSYLEALDAFFLRGQQKGVFRIDITAAVFTELFITLVYGMVDA	158
HE2011311	FEQNPGRHAGHGD-ASWQSYVEALDAFFLRGQQKRVFRIDISAATFSELFIVLIYGMVDA	179
HE2011471	FEQNPGRHAGHGD-ASWQSYVEALDAFFLRGQQKRVFRIDISAATFSELFIVLIYGMVDA	179
HE2105886	FEQNPGRHAGHGD-ASWQSYVEALDAFFLRGQQKRVFRIDISAATFSELFIVLIYGMVDA	179
	*: *: * *******************************	
PAO1nfxB	ERRGRAASSNSAHTLEQMFLHGASNPARS 187	
HE2011311	ERRGRAASAGLSATLEELFLRGASNPAQPASP 211	
HE2011471	ERRGRAASAGLSATLEELFLRGASNPAQPASP 211	
HE2105886	ERRGRAASAGLSATLEELFLRGASNPAQPASP 211	

402 Figure S2.

401



Protein	Mechanism	Mutations ¹
AmpC	Structural change	G27D, T105A, V205L, V356I, G391A
AmpD	AmpC overexpression	None
AmpDh2	AmpC overexpression	V40I
AmpDh3	AmpC overexpression	None
AmpR	AmpC overexpression	G283E, M288R
ArmZ	MexXY overexpression	C40R, L88P, S112N, D119E, I237V, V243A
DacB	AmpC overexpression	None
DacC	PBP5	None
Ftsl	PBP3	G8S
FusA1	Elongation factor G	H166D
GalU	Lipopolisacharide synthesis	None
GyrA	DNA gyrase (subunit A)	None
GyrB	DNA gyrase (subunit B)	S466F
MexA	Intrinsic antibiotic resistance	A111T
MexB	Intrinsic antibiotic resistance	G957D, S1041E, V1042A
MexC	MexCD overexpression	E251Q,A262E,A277T,H310R,S330A,A378T,A384V
MexD	MexCD overexpression	T87S,S845A
MexE	MexEF overexpression	None
MexF	MexEF overexpression	None
MexR	MexAB overexpression	M1_L13del, V132A

420	MexS	MexEF overexpression/OprD downregulation	V73A, D249N	
	MexT	MexEF overexpression/OprD downregulation	M1_A78del, F172l	
421	MexX	Intrinsic antibiotic resistance	A30T, K329Q, L331V, W358R	
177	MexY	Intrinsic antibiotic resistance	I536V, T543A, G589A,Q840E, N1036T	
422	MexZ	MexXY overexpression	G89S	
423	Mpl	Recycling of cell wall components	R73C	
		(AmpC overexpression)		
424	NalC	MexAB overexpression	G71E, D79E, S209R	
727	NalD	MexAB overexpression	None	
425	NfxB	MexCD overexpression	none (HE2011025,HE2040684)	
			multiple (HE2011311, HE2011471,HE2105886) ²	
426	OprD	Inactivation OprD	T103S,K115T,F170L,P186G,V189T,R310E,A315G,G425	
			Α	
427	OprJ	MexCD overexpression	None	
	OprM	Intrinsic antibiotic resistance	None	
428	OprN	MexEF overexpression	S13P	
	ParC	DNA topoisomerase IV (subunit A)	P752T	
429	ParE	DNA topoisomerase IV (subunit B)	D533E	
	ParR	MexXY and MexEF overexpression/ OprD	S170N,L153R	
430		downregulation		
	ParS	MexXY overexpression/OprD downregulation	aa70InsPR, H398R	
431	PbpA	PBP2	None	
	PmrA	Lipopolisacharide synthesis	None	
	PmrB	Lipopolisacharide synthesis	S2P, A4T, V15I, G68S, Y345H	

432 433 ¹Mutations described previously as natural polymorphisms are in bold type ²See multiple alignment sequences using Clustal (EMBL-EBI) in Figure S2.

434 Table S1.

Protein	Function	Phage Infection (References)	SNP (HE2011471:HE21058)	Aminoacid change (HE2011471:HE21058)	Quorum Sensing (References)		
	Receptors/Pilus/Regulators/Efflux pumps Transport: Antimicrobial susceptibility						
FemA receptor	Siderophore transport Iron transport	Phage receptor (1)	G>T	A274D	(2)		
TonB- dependent receptor	Antibiotic efflux. Iron transport	Phage receptor (3)	G>A	P679L	(2)		
Filamentous haemagglutinin pilus	Surface adhesion	Phage receptor(4)	T>G; GGCCGGCAGTCTGCTCG GCGAGGCTCTGGACCTG CCCGCC>G; A>C; T>G; T>G	V1881G; del2874-2887; T2888P; L2890R; L2896R	(5)		
Transcriptional regulator, AcrR family	Efflux pumps regulation	Phage receptor (6)	C>T	S36F	(7)		
Magnesium and cobalt efflux CorC	lon Resistance. Target of the bacteriocin	Phage receptor (8)	T>G	T213P	(9)		
Quorum Sensing activation							
Acyl-homoserine lactone acylase PvdQ, quorum-quenching	Quorum sensing inhibition. Virulence	Phage Resistance (10)	GC	H695T; Q696S; L697Y; H698I; P699Q; T700L; G701V; D702T; L703F; R705E; del706708; Q709E; S711P; R712K; V713A; A714R; F716L; P718A; V719F; Q720S; R721Q; A723S	(11)		

Prophages: Resistance to Lytic Phage Infection						
Zona occludens toxin	Filamentous Prophage assembly	Phage Resistance (12)	T>C	S244W; M249L; V251T; A254G; del255- 280	(12)	
Phage terminase, large subunit GpA	Prophage assembly	Phage Resistance (13)	Ins1-84; G>A	ins1-28; A355T	(12)	
Prophage Clp protease	Prophage	Phage Resistance (14)	C>T	V134G	(15)	
Small molecules: Resistance to Lytic Phage Infection						
SAM-dependent methyltransfere YafE	Aminoglycoside regulation	Phage Resistance (16)	C>T	V134G	(17)	
TA systems: Resistance to Lytic Phage Infection						
HipBA toxin- antitoxin	Persistence	Phage Resistance (18)	A>C	C432R	(19)	
Oxidative Stress/Secretion Systems/Virulence: Response to Lytic Phage Infection						
Flavodoxin reductases	Tolerance to oxidative stress	Phage infection (20)	C>A	R39L	(21)	
Catalase KatE		Phage infection (22)	C>T	R358H	(23)	
T1SS secreted agglutinin RTX	Secretion Systems	Phage infection (24)	G>T	P695T	(25)	

Transcriptional anti- antiactivator ExsC T3SS		Phage infection (26)	C>T	G66E	(25)
VgrG protein Effector of the T6SS		Phage infection (27)	T>C	L32P	(25)
VgrG protein Effector of the T6SS		Phage infection (27)	A>G	V43M	(25)
Pyoverdine synthetase PvdL	Virulence	Phage infection (28)	T>G	D1938A; L2241V; L2243M; L2247I; G2252A; L2254M; L2266V; L2272E; L2275Q; Q2276A; I2279M	(29)
Cis/trans isomerase		Virulence; resistance to cell wall solvents. (30)	G>T	P82T	(31)
lsocitrate dehydrogenase [NADP]		Glyoxylate shunt linked with virulence. (32)	A>C	T474P	(33)
MOSC domain- containing protein		Molibdenum cofactor. Biosynthesis of Moco (33)	T>G	V25G	(34)
GTP 3',8-cyclase Molibdenum		Biosynthesis of Moco (35)	A>C	T257P	(34)
Phosphate synthase II PhzC (chorismate)		Phenazine biosynthesis. (36)	del765-834	del255-278	(37)

435 **Table S2.**

436 REFERENCES. MATERIAL SUPPLEMENTARY

437

Sundarrajan S, Raghupatil J, Vipra A, Narasimhaswamy N, Saravanan S,
 Appaiah C, et al. Bacteriophage-derived CHAP domain protein, P128, kills
 Staphylococcus cells by cleaving interpeptide cross-bridge of peptidoglycan.
 Microbiology (Reading). 2014;160(Pt 10):2157-69.

442 2. Cornelis P, Matthijs S, Van Oeffelen L. Iron uptake regulation in
443 *Pseudomonas aeruginosa*. Biometals. 2009;22(1):15-22.

3. Rabsch W, Ma L, Wiley G, Najar FZ, Kaserer W, Schuerch DW, et al.
FepA- and TonB-dependent bacteriophage H8: receptor binding and genomic
sequence. J Bacteriol. 2007;189(15):5658-74.

447 4. Jouravleva EA, McDonald GA, Marsh JW, Taylor RK, Boesman448 Finkelstein M, Finkelstein RA. The *Vibrio cholerae* mannose-sensitive
449 hemagglutinin is the receptor for a filamentous bacteriophage from *V. cholerae*450 O139. Infect Immun. 1998;66(6):2535-9.

5. Sun J, Li X, Qiu Y, Xue X, Zhang M, Yang W, et al. Quorum sensing
regulates transcription of the pilin gene mshA1 of MSHA pilus in *Vibrio parahaemolyticus*. Gene. 2022;807:145961.

454 6. Nazarov PA. MDR Pumps as Crossroads of Resistance: Antibiotics and
455 Bacteriophages. Antibiotics (Basel). 2022;11(6).

7. Chin-A-Woeng TF, van den Broek D, Lugtenberg BJ, Bloemberg GV.
The *Pseudomonas chlororaphis* PCL1391 sigma regulator psrA represses the
production of the antifungal metabolite phenazine-1-carboxamide. Mol Plant
Microbe Interact. 2005;18(3):244-53.

8. Bohm K, Porwollik S, Chu W, Dover JA, Gilcrease EB, Casjens SR, et al.
Genes affecting progression of bacteriophage P22 infection in *Salmonella*identified by transposon and single gene deletion screens. Mol Microbiol.
2018;108(3):288-305.

Hounmanou YMG, Leekitcharoenphon P, Hendriksen RS, Dougnon TV,
Mdegela RH, Olsen JE, et al. Surveillance and Genomics of Toxigenic *Vibrio cholerae* O1 From Fish, Phytoplankton and Water in Lake Victoria, Tanzania.
Front Microbiol. 2019;10:901.

468 10. León-Félix J, Villicaña C. The impact of quorum sensing on the 469 modulation of phage-host interactions. J Bacteriol. 2021.

470 11. Utari PD, Setroikromo R, Melgert BN, Quax WJ. PvdQ Quorum
471 Quenching Acylase Attenuates *Pseudomonas aeruginosa* Virulence in a Mouse
472 Model of Pulmonary Infection Front Cell Infect Microbiol. 2018;8:119.

473 12. Ambroa A, Blasco L, López-Causapé C, Trastoy R, Fernandez-García L,
474 Bleriot I, et al. Temperate Bacteriophages (Prophages) in *Pseudomonas*475 *aeruginosa* Isolates Belonging to the International Cystic Fibrosis Clone

- 476 (CC274).
- 477 . Front Microbiol. 2020;11:556706.

478 13. Owen SV, Wenner N, Dulberger CL, Rodwell EV, Bowers-Barnard A,
479 Quinones-Olvera N, et al. Prophages encode phage-defense systems with
480 cognate self-immunity. Cell Host Microbe. 2021;29(11):1620-33.e8.

481 14. Geuskens V, Mhammedi-Alaoui A, Desmet L, Toussaint A. Virulence in
482 bacteriophage Mu: a case of trans-dominant proteolysis by the *Escherichia coli*483 Clp serine protease. EMBO J. 1992;11(13):5121-7.

Yang N, Lan L. *Pseudomonas aeruginosa* Lon and ClpXP proteases:
roles in linking carbon catabolite repression system with quorum-sensing
system. Curr Genet. 2016;62(1):1-6.

487 16. Hardy A, Kever L, Frunzke J. Antiphage small molecules produced by
488 bacteria - beyond protein-mediated defenses. Trends Microbiol. 2023;31(1):92489 106.

490 17. Kang Y, Kim H, Goo E, Jeong H, An JH, Hwang I. Unraveling the role of
491 quorum sensing-dependent metabolic homeostasis of the activated methyl
492 cycle in a cooperative population of *Burkholderia glumae*. Sci Rep.
493 2019;9(1):11038.

494 18. LeRoux M, Laub MT. Toxin-Antitoxin Systems as Phage Defense
495 Elements. Annu Rev Microbiol. 2022;76:21-43.

Hemati S, Azizi-Jalilian F, Pakzad I, Taherikalani M, Maleki A, Karimi S,
et al. The correlation between the presence of quorum sensing, toxin-antitoxin
system genes and MIC values with ability of biofilm formation in clinical isolates
of *Pseudomonas aeruginosa*. Iran J Microbiol. 2014;6(3):133-9.

20. Lamb DC, Follmer AH, Goldstone JV, Nelson DR, Warrilow AG, Price
CL, et al. On the occurrence of cytochrome P450 in viruses. Proc Natl Acad Sci
U S A. 2019;116(25):12343-52.

Moyano AJ, Tobares RA, Rizzi YS, Krapp AR, Mondotte JA, Bocco JL, et
al. A long-chain flavodoxin protects *Pseudomonas aeruginosa* from oxidative
stress and host bacterial clearance. PLoS Genet. 2014;10(2):e1004163.

506 22. Mancini S, Imlay JA. The induction of two biosynthetic enzymes helps 507 *Escherichia coli* sustain heme synthesis and activate catalase during hydrogen 508 peroxide stress. Mol Microbiol. 2015;96(4):744-63.

Liao H, Zhong X, Xu L, Ma Q, Wang Y, Cai Y, et al. Quorum-sensing
systems trigger catalase expression to reverse the oxyR deletion-mediated
VBNC state in *Salmonella typhimurium*. Res Microbiol. 2019;170(2):65-73.

512 24. Zhou W, Li Y, Li Z, Ma B, Jiang X, Hu C, et al. Genomic Changes and 513 Genetic Divergence of. Front Microbiol. 2021;12:710262.

25. Pena RT, Blasco L, Ambroa A, Gonzalez-Pedrajo B, Fernandez-Garcia
L, Lopez M, et al. Relationship Between Quorum Sensing and Secretion
Systems. Front Microbiol. 2019;10:1100.

26. Nakamura K, Ogura Y, Gotoh Y, Hayashi T. Prophages integrating into
prophages: A mechanism to accumulate type III secretion effector genes and
duplicate Shiga toxin-encoding prophages in *Escherichia coli*. PLoS Pathog.
2021;17(4):e1009073.

521 27. Navarro-Garcia F, Ruiz-Perez F, Cataldi Á, Larzábal M. Type VI 522 Secretion System in Pathogenic *Yersinia*. Front Microbiol. 2019;10:1965.

523 28. Hosseinidoust Z, Tufenkji N, van de Ven TG. Predation in homogeneous 524 and heterogeneous phage environments affects virulence determinants of 525 *Pseudomonas aeruginosa*. Appl Environ Microbiol. 2013;79(9):2862-71.

Y Ramírez-Rueda R, Salvador MJ. Phenotypic detection of quorum
sensing inhibition in *Pseudomonas aeruginosa* pyoverdine and swarming by
volatile organic products. Future Microbiol. 2020;15:1147-56.

30. Bothmann H, Pluckthun A. The periplasmic *Escherichia coli* peptidylprolyl
cis,trans-isomerase FkpA. I. Increased functional expression of antibody
fragments with and without cis-prolines. J Biol Chem. 2000;275(22):17100-5.

532 31. Ünal CM, Steinert M. Microbial peptidyl-prolyl cis/trans isomerases
533 (PPIases): virulence factors and potential alternative drug targets. Microbiol Mol
534 Biol Rev. 2014;78(3):544-71.

535 32. Wang FS, Whittam TS, Selander RK. Evolutionary genetics of the 536 isocitrate dehydrogenase gene (icd) in *Escherichia coli* and *Salmonella* 537 *enterica*. J Bacteriol. 1997;179(21):6551-9.

33. Yan C, Li X, Zhang G, Zhu Y, Bi J, Hao H, et al. Quorum SensingMediated and Growth Phase-Dependent Regulation of Metabolic Pathways in *Hafnia alvei* H4. Front Microbiol. 2021;12:567942.

541 34. Filiatrault MJ, Tombline G, Wagner VE, Van Alst N, Rumbaugh K, Sokol
542 P, et al. *Pseudomonas aeruginosa* PA1006, which plays a role in molybdenum
543 homeostasis, is required for nitrate utilization, biofilm formation, and virulence.
544 PLoS One. 2013;8(2):e55594.

Shanmugam KT, Stewart V, Gunsalus RP, Boxer DH, Cole JA, Chippaux
M, et al. Proposed nomenclature for the genes involved in molybdenum
metabolism in *Escherichia coli* and *Salmonella typhimurium*. Mol Microbiol.
1992;6(22):3452-4.

549 36. Chen Y, Shen X, Peng H, Hu H, Wang W, Zhang X. Comparative 550 genomic analysis and phenazine production of *Pseudomonas chlororaphis*, a 551 plant growth-promoting rhizobacterium. Genom Data. 2015;4:33-42.

Wang Z, Huang X, Jan M, Kong D, Wang W, Zhang X. Lon protease
downregulates phenazine-1-carboxamide biosynthesis by degrading the
quorum sensing signal synthase Phzl and exhibits negative feedback regulation
of Lon itself in *Pseudomonas chlororaphis* HT66. Mol Microbiol.
2021;116(2):690-706.

- 557
- 558